Document:

Exhibit 10.17

TO Pharmaceuticals LLC

77 Water Street, 8th floor

New York, New York 10005

 

October 19, 2018

 

Mr. Seth Yakatan

PO Box 2140

Manhattan Beach, CA 90267

 

MANAGEMENT CONSULTING AGREEMENT

 

Dear Seth:

 

We are very pleased to offer you the position
of Interim Chief Executive Officer (“CEO”) of TO Pharmaceuticals LLC, a Delaware limited liability company (the “Company”),
effective as of October 1, 2018. This offer of is conditioned on your satisfactory completion of certain requirements, as more
fully explained in this letter. Your role as CEO will be subject to the terms and conditions set forth in this letter, which supersede
anything said or communicated to you during any discussions or correspondence about your employment with the Company or its affiliates.
Your firm, Sutherland Paige and Associates, Inc. D/B/A Katan Associates, International (“Katan”), will be engaged as
an consultant and independent contractor to the Company to provide your services on an interim basis until you and the Company
enter into a definitive employment agreement (the “Employment Agreement”).

 

Your position with the Company will be full-time,
effective immediately. This will be an exempt executive position. In your capacity as CEO, you will perform duties and responsibilities
that are reasonable and consistent with such position, and as may be assigned to you from time to time by the Company’s board
of managers (the “Board”) or its designees, in connection with which you will be generally responsible for the Company’s
operations and affairs, including without limitation completion of its financial statements, financing activities and the Company’s
merger with a public company or other public listing. You agree to devote as much time as is required and best efforts to the performance
of your duties and to the furtherance of the Company's interests, and to be subject to the Company’s customary confidentiality
and work-for-hire provisions. The Company acknowledges that Katan and Seth Yakatan may be involved in other projects during the
term of this agreement and that such efforts may require some of Seth Yakatan’s time and attention, which will not unreasonably
interfere with his duties to the Company.

 

In consideration of your services, Katan will
receive a salary of $12,500 per month; provided, that until the Company raises at least $3,000,000 in gross proceeds from one or
more financing transactions (the “3M Financing”) after the date hereof (not including any advances to the Company from
T.O. Global LLC or any affiliate thereof), the Company will pay Katan at a rate of $5,000 per month in cash billable each month
and payable within 15 days of presentation of invoices, and the remaining $7,500 per month will be deferred. The deferred amount
shall be payable solely out of the proceeds of the $3M Financing. In addition, the Company will reimburse you or Katan for reasonable
business expenses you incur on behalf of the Company, including travel expenses, upon submission of evidence thereof consistent
with the Company’s expense reimbursement policy.

 

    	 	1	 

     

    

 

In addition, you will become eligible for participation
in the equity of the Company’s successor through a grant of options to purchase common stock of such successor. The exercise
price of such options shall be based on a fair market value determined by the equity value of such successor in connection its
round of financing (the “Concurrent Financing”) to be raised substantially concurrently with having a class of equity
securities (the “Public Stock”) listed for trading on Nasdaq (the “Listing”; and collectively with Concurrent
Financing, referred to herein as “Going Public”); however, all options shall be issued with a cashless exercise feature.
Your aggregate option grant would be for 3% of the Public Stock, after giving effect to Going Public, subject to vesting as follows:

 

		(a)	One-third upon (i) (A) the Listing, and (B) such successor having raised at least $10,000,000 from
the Concurrent Financing; and (ii) you having been employed by the Company for at least six months after Going Public;

 

		(b)	One-third upon (i) the product of (A) the number of issued and outstanding shares of Public Stock,
and (B) the volume weighted average of the closing price of the Public Stock for a period of 20 consecutive trading days, equalling
or exceeding $100,000,000 on or prior to June 30, 2019, and (ii) you having been employed by the Company for at least 1 year after
Going Public; and

 

		(c)	One-third upon the Company’s completion of two phase 2 clinical studies with a plan for FDA
new drug approval through a phase 3 study in the USA.

 

Until the execution and delivery of the Employment
Agreement, your engagement and position as interim CEO will be at-will, meaning that you or the Company may terminate the relationship
at any time, with or without cause, and with or without notice. The Company acknowledges that regardless of termination, any historical
cash or accrual amounts owed to the Company shall be payable and due in accordance with the terms hereof. The Company cannot wilfully
terminate this Agreement for the express purpose of avoiding vesting of the option subject to paragraph (a) above.

 

This offer is contingent upon:

 

(a) Verification of your right to
work in the United States, as demonstrated by your completion of the I-9 form upon hire and your submission of acceptable documentation
(as noted on the I-9 form) verifying your identity and work authorization within three days of starting employment;

 

(b) Satisfactory completion of a
background investigation, for which the required notice and consent forms are attached to this letter; and

 

(c) Your execution of the Company’s
customary confidentiality and work-for-hire agreement and employee handbook;

 

This offer will be withdrawn if any
of the above conditions are not satisfied.

 

    	 	2	 

     

    

 

By accepting this offer, you confirm that you
are able to accept your responsibilities and carry out the work that it would involve without breaching any legal restrictions
on your activities, such as restrictions imposed by a current or former employer or client. You also confirm that you will inform
the Company about any such restrictions and provide the Company with as much information about them as possible, including any
agreements between you and your current or former employer or client describing such restrictions on your activities. Such activities
shall be disclosed in Exhibit A to this Agreement.

 

You further confirm that you will not remove
or take any documents or proprietary data or materials of any kind, electronic or otherwise, with you from your current or former
employer or client(s) to the Company without written authorization from your current or former employer and/or client(s), nor will
you use or disclose any such confidential information during the course and scope of your employment with the Company. If you have
any questions about the ownership of particular documents or other information, discuss such questions with your former employer
and/or client(s) before removing or copying the documents or information.

 

This Offer Letter shall be governed by and
construed in accordance with the laws of the State of New York without regard to the conflict of laws principles thereof. State
and federal courts sitting in the City of New York shall have exclusive jurisdiction to hear any dispute arising under this Offer
Letter.

 

All of us at the Company are excited at the
prospect of you joining our team. If you have any questions about the above details, please call me immediately. If you wish to
accept this position, please sign below and return this letter agreement to me within 3 days. This offer is open for you to accept
until October 21, 2018, at which time it will be deemed to be withdrawn.

 

    	 	3	 

     

    

 

I look forward to hearing from you.

 

Yours sincerely,

 

TO PHARMACEUTICALS LLC

 

	By:	/s/ Bernard Sucher	 	 
	Name:	Bernard Sucher	 	 
	Title:	Authorized Representative	 	 

 

Accepted:

 

	/s/ Seth Yakatan	 	 
	Seth Yakatan	 	 

 

    	 	4	 

     

    

 

Exhibit
A

 

Disclosure
on past and current clients in which Seth Yakatan / Katan is/was involved:

 

Past
Roles:

 

		1.	Seth Yakatan/Katan
acted as interim CEO and a board member of Kalytera Therapeutics, Inc. from January 2014 until July 2017. No current relationship
exists with this company and Seth Yakatan/Katan is not bound by any non-competition or confidentiality agreement with Kalytera.
Seth Yakatan/Katan is a shareholder in Kalytera and owns 800,000 shares in the company.

 

		2.	Seth Yakatan/Katan
acted as a consultant to GB Sciences, Inc. from January 2018 until March 2018. No current relationship exists with the company
and Seth Yakatan/Katan is not bound by any non-competition or confidentiality agreement with GB. Seth Yakatan/Katan is a shareholder
in GB and owns 25,000 shares in the company.

 

		3.	Seth Yakatan/Katan
acted as a consultant to Ocean Grown Ventures, LLC. from April 2018 until August 2018. No current relationship exists with the
company and Seth Yakatan/Katan is not bound by any non-competition or confidentiality agreement with Ocean Grown. Seth Yakatan/Katan
is a shareholder in Ocean Grown and owns shares in the company equivalent to 1.5% of the outstanding equity of Ocean Grown.

 

		4.	Seth Yakatan/Katan
has acted as a consultant to Jay Pharma/Tikun Pharma from March 2018 until the date of execution of this agreement. Such agreement
is still in place.

 

		5.	Seth Yakatan/Katan
has acted as a consultant to Electrum Partners from June 2017 until the date of execution of this agreement. Such agreement is
still in place and may remain in place until the employment agreement is entered into.

 

    	 	5Exhibit 10.19

 

THIS WARRANT AND THE SECURITIES ISSUABLE
UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF,
AND MAY NOT BE SOLD, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT AND SUCH STATE SECURITIES LAWS.

 

VOID AFTER 5:00 P.M. ON MARCH 9, 2023

 

TO PHARMACEUTICALS LLC

 

WARRANT TO PURCHASE UNITS

 

Carle Place,
New York

Certificate
No. 1

 

THIS IS TO CERTIFY
THAT, for value received, Sidney Taubenfeld, an individual residing at 247 West 87th Street, Apt. 7G, New York, New York 10024
(the “Warrantholder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to
purchase from TO PHARMACEUTICALS LLC, a Delaware limited liability (the “Company”), up to 500 units (the “Warrant
Units”) of the membership interests of the Company (“Units”), at an exercise price equal to $700 per Unit (the
“Exercise Price”) at the times and in the manner set forth below.

 

As provided herein,
the Exercise Price and the number of Warrant Units which may be purchased upon the exercise of this Warrant are, upon the happening
of certain events, subject to modification and adjustment.

 

The rights of the registered
holder of this Warrant shall be subject to the following further terms and conditions:

 

		1.	Exercise of Warrant; Payment of Exercise Price.

 

		(a)	Exercise of Warrant.

 

(i)       While
this Warrant remains outstanding, this Warrant shall be exercisable, in whole or in part, as of the date hereof (the “Exercisability
Date”), with the exercise form attached as Exhibit A hereto (the “Exercise Form”) duly executed by the
Warrantholder or by the Warrantholder’s duly authorized attorney-in-fact, at the principal office of the Company, or at such
other office or agency in the United States as the Company may designate by notice in writing to the Warrantholder (in either event,
the “Company Offices”), accompanied by payment in accordance with Section 1(b), of the aggregate Exercise Price payable
for the Warrant Units being purchased. If the Warrantholder exercises the Warrant for fewer than all of the Warrant Units issuable
in accordance with this Warrant, the Company shall, upon each exercise prior to the Expiration Date, execute and deliver to the
Warrantholder a new Warrant (dated as of the date hereof) evidencing the balance of the Units that remain subject to issuance upon
the exercise of this Warrant. This Warrant shall expire on the seventh (7th) anniversary of the date hereof (the “Expiration
Date”), and thereupon the Warrantholder shall surrender this Warrant.

 

(ii)       On
the date of exercise of this Warrant, upon the the Warrantholder exercising same in compliance with the terms hereof, and if previous
to such exercise the Warrantholder is not a party to the operating agreement of the Company, upon the execution and delivery to
the Company of the joinder agreement in the form attached hereto as Exhibit B, the Warrantholder shall be deemed to have
become the holder of record for all purposes of the Units to which the exercise relates.

 

    	 		 

     

    

 

(iii)       As
soon as practicable after the exercise of all or part of this Warrant, the Company, at its expense (including the payment by it
of any applicable issue taxes), will cause to be issued in the name of and delivered to the Warrantholder a certificate or certificates
evidencing the number of duly authorized, validly issued, fully paid and nonassessable Units to which the Warrantholder shall be
entitled upon such exercise, if the units of membership interests of the Company are certificated as of such time.

 

(iv)       Any
portion of this Warrant, except as otherwise provided in paragraph (b) below, shall become exercisable at the times and in the
amounts set forth below (with respect to each tranche and sub-tranche of exercisability, the “Exercisability Date”)
until this Warrant expires, so long as the Warrantholder is an employee of the Company or one of its subsidiaries, or Tikun Olam
Holding Group LLC, a New York limited liability company (“TOHG”, and together with the Company and its subsidiaries
herein referred to as the “Company Group”) as of the Exercisability Date. Except as otherwise provided in paragraphs
(b)(i) through (iii) below, upon the termination of the employment by the Company Group of Warrantholder for any reason (whether
by the Company Group or by Warrantholder), any portion of this Warrant that is not exercisable as of such termination shall be
automatically cancelled and surrendered to the Company:

 

	Number of Units	 	Exercisability Date
	75	 	September 9, 2016
	50	 	March 9, 2017
	175* (15.9091 per month*)	 	On the 9th day of each of April 2017 through February 2018
	200	 	March 9, 2018
	100	 	The Company having a valuation of $100 million or more**
	100	 	The Company having a valuation of $200 million or more**

 

** For these purposes, the Company’s
valuation will be equal to the pre-transaction equity value of the Company in connection with its most recently completed financing
transaction.

 

		(b)	Certain Limitations.

 

(i)          The
portion of this Warrant that is exercisable for 75 Units on September 9, 2016 (the “75 Warrant Tranche”) shall remain
exercisable by the Warrantholder or his successors or assigns for the period from the Exercisability Date until this Warrant expires
regardless of whether the Warrantholder is an employee of the Company Group as of the date of such exercise, except in the following
circumstances:

 

(A)          If
prior to the first anniversary of the date hereof, the employment of Warrantholder has been terminated by the Company Group “for
cause” as set forth in section 9(a) of that certain Employment Agreement of even date herewith between the Company and Warrantholder
(the “Employment Agreement”); or

 

(B)          If
prior to the first anniversary of the date hereof, the Warrantholder voluntarily terminates his employment with the Company Group.

 

(ii)          If
prior to the Exercisability Date for the initial 75 Warrant Tranche, the Warrantholder dies or becomes Disabled, then the 75 Warrant
Tranche shall be automatically cancelled and surrendered to the Company.

 

(iii)          Except
as provided by paragraph (ii) above, if prior to the Exercisability Date for the initial 75 Warrant Tranche, the employment by
the Company Group of Warrantholder has been terminated without cause as set forth in section 9(a) of the Employment Agreement,
the 75 Warrant Tranche shall remain exercisable through the Expiration Date.

 

    	 	2	 

     

    

 

(iv)          The
portions of this Warrant that are exercisable for 100 Units, upon the occurrence of the Company having a valuation in excess of
$100 million or $200 million, respectively (collectively, the “200 Warrant Tranche”) shall remain exercisable by the
Warrantholder or his successors or assigns for the period from the Exercisability Date until this Warrant expires, except if at
any time the employment of Warrantholder has been terminated by the Company Group “for cause” as set forth in section
9(a) of the Employment Agreement. Any portion of the 200 Warrant Tranche that has not been exercised as of the date of such termination
for cause, if such termination should occur after the second anniversary of the date hereof, shall be automatically cancelled and
surrendered to the Company.

 

(v)          This
Warrant and any Units issued pursuant to this Warrant are subject to the terms and conditions of that certain Repurchase Agreement
of even date herewith between the Company and the Warrantholder during the term of such agreement.

 

(vi)          This
Warrant shall become immediately exercisable upon (a) the acquisition of a majority of the voting power of the Company by a person
or entity or group of persons or entities by means of any transaction or series of related transactions (including without limitation
any stock acquisition, reorganization, merger or consolidation, but excluding any sale of stock for capital raising purposes);
or (b) a sale or other disposition of all or substantially all of the assets of the Company (and any subsidiaries, taken as a whole)
by means of any transaction or series of related transactions, except where such sale, lease or other disposition is to a wholly-owned
subsidiary of the Company.

 

(c)          Payment
of Exercise Price. Payment of the Exercise Price shall be made, at the option of the Warrantholder as expressed in the Exercise
Form, by the following methods:

 

(i)          by
delivery to the Company of a certified or official bank check payable to the order of the Company or by wire transfer of immediately
available funds to an account designated in writing by the Company, in the amount of such aggregate Exercise Price for Warrant
Units being purchased hereunder;

 

(ii)          by
instructing the Company to withhold a number of Warrant Units then issuable upon exercise of this Warrant with an aggregate fair
market value (“Fair Market Value”), as determined in good faith by the Board of Directors of the Company as of the
Exercise Date, equal to the aggregate Exercise Price for Warrant Units being purchased hereunder;

 

(iii)          by
surrendering to the Company (x) Warrant Units previously acquired by the Warrantholder with an aggregate Fair Market Value as of
the Exercise Date equal to the aggregate Exercise Price for Warrant Units being purchased hereunder and/or (y) other securities
of the Company having a value as of the Exercise Date equal to the aggregate Exercise Price for Warrant Units being purchased hereunder
(which value in the case of debt securities shall be the principal amount thereof plus accrued and unpaid interest, in the case
of preferred stock shall be the liquidation value thereof plus accumulated and unpaid dividends, and in the case of Units shall
be the Fair Market Value thereof); or

 

(iv)          any
combination of the foregoing.

 

In the event of any withholding of Warrant
Units or surrender of other equity securities pursuant to clause (c)(ii), or (iii) above where the number of Units whose value
is equal to the aggregate Exercise Price is not a whole number, the number of Units withheld by or surrendered to the Company shall
be rounded up to the nearest whole unit and the Company shall make a cash payment to the Warrantholder (by delivery of a certified
or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of a Unit being so
withheld by or surrendered to the Company in an amount equal to the product of (x) such incremental fraction of a Unit being so
withheld or surrendered multiplied by (y) in the case of Units, the Fair Market Value per Warrant Unit as of the Exercise Date,
and, in all other cases, the value thereof as of the Exercise Date determined in accordance with clause (iii)(y) above.

 

		2.	Issuance of Units; Reservation of Units.

 

(a)          The
Company covenants and agrees that all Units which may be issued upon the exercise of all or part of this Warrant will, upon issuance
in accordance with the terms hereof, be validly issued and free from all taxes, liens and charges with respect to the issue thereof.

 

    	 	3	 

     

    

 

(b)          The
Company further covenants and agrees that if any Units to be reserved for the purpose of the issuance of Units upon the exercise
of this Warrant require registration with, or approval of, any governmental authority under any federal or state law before such
Units may be validly issued or delivered upon exercise, then the Company will promptly use its best efforts to effect such registration
or obtain such approval, as the case may be.

 

3.       Adjustments
of Exercise Price, Number and Character of Warrant Units, and Number of Warrants.

 

The Exercise Price and
the number and kind of securities purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time
upon the happening of the events enumerated in this Section 3.

 

(a)          Distributions,
Subdivisions and Combinations. In case the Company shall at any time on or before the Expiration Date:

 

(i)          pay
or make a distribution in Units or other securities of the Company to holders of all its outstanding Units;

 

(ii)         subdivide
or reclassify the outstanding Units into a greater number of Units;

 

(iii)         combine
the outstanding Units into a smaller number of Units; or

 

(iv)         issue
by reclassification of its Units other securities of the Company (including any such reclassification in connection with a consolidation
or merger in which the Company is the continuing corporation),

 

then the number and kind of securities
purchasable upon exercise of this Warrant outstanding immediately prior thereto shall be adjusted so that the Warrantholder shall
be entitled to receive the kind and number of Units or other securities of the Company which the Warrantholder would have owned
or have been entitled to receive after the happening of any of the events described above had this Warrant been exercised in full
immediately prior to the earlier of the happening of such event or any record date in respect thereto. In the event of any adjustment
of the number of Units or other securities of the Company purchasable upon the exercise of this Warrant pursuant to this Paragraph
3(a), the Exercise Price shall be adjusted to be the amount resulting from dividing the number of Units (including fractional Units)
covered by this Warrant immediately after such adjustment into the total amount payable upon exercise of this Warrant in full immediately
prior to such adjustment. An adjustment made pursuant to this Paragraph 3(a) shall become effective immediately after the effective
date of such event retroactive to the record date for any such event. Such adjustment shall be made successively whenever any event
listed above shall occur.

 

(b)          Extraordinary
Dividends. In case the Company shall at any time on or before the Expiration Date fix a record date for the issuance of rights,
options, or warrants to all holders of its outstanding Units, entitling them (for a period expiring within 45 days after such record
date) to subscribe for or purchase Units (or securities exchangeable for or convertible into Units) at a price per Unit (or having
an exchange or conversion price per Unit, with respect to a security exchangeable for or convertible into Units) which is lower
than the current Exercise Price per Unit (as defined in Paragraph 3(d) below) on such record date, then the Exercise Price shall
be adjusted by multiplying the Exercise Price in effect immediately prior to such record date by a fraction, of which (i) the numerator
shall be the number of Units outstanding on such record date plus the number of Units which the aggregate offering price
of the total number of Units so to be offered (or the aggregate initial exchange or conversion price of the exchangeable or convertible
securities so to be offered) would purchase at such current Exercise Price and (ii) the denominator shall be the number of Units
outstanding on such record date plus the number of additional Units to be offered for subscription or purchase (or into which the
exchangeable or convertible securities so to be offered are initially exchangeable or convertible). Such adjustment shall become
effective at the close of business on such record date; however, to the extent that Units (or securities exchangeable for or convertible
into Units) are not delivered after the expiration of such rights, options, or warrants, the Exercise Price shall be readjusted
(but only with respect to any portion of this Warrant exercised after such expiration) to the Exercise Price which would then be
in effect had the adjustments made upon the issuance of such rights, options, or warrants been made upon the basis of delivery
of only the number of Units (or securities exchangeable for or convertible into Units) actually issued. In case any subscription
price may be paid in a consideration part or all of which shall be in a form other than cash, the value of such consideration shall
be as determined in good faith by the Board of Directors of the Company and shall be described in a statement mailed to the Warrantholder.
Units owned by or held for the account of the Company shall not be deemed outstanding for the purpose of any such computation.

 

    	 	4	 

     

    

 

(c)          Extraordinary
Distributions. In case the Company shall at any time after the original date of issuance of this Warrant distribute to all
holders of its Units (including any such distribution made in connection with a consolidation or merger in which the Company is
the surviving corporation) evidences of its indebtedness or assets (excluding cash dividends and distributions payable out of consolidated
net income or earned surplus in accordance with New York law and dividends or distributions payable in Units of stock described
in Paragraph 3(a) above) or rights, options, or warrants or exchangeable or convertible securities containing the right to subscribe
for or purchase Units (or securities exchangeable for or convertible into Units), then the Exercise Price shall be adjusted by
multiplying the Exercise Price in effect immediately prior to the record date for such distribution by a fraction, of which (i)
the numerator shall be the current Exercise Price per Unit of the portion of the evidences of indebtedness or assets so to be distributed
or of such rights, options or warrants applicable to one Unit and (ii) the denominator shall be such current Exercise Price per
Unit. Such adjustment shall be made whenever any such distribution is made, and shall become effective on the date of distribution
retroactive to the record date for such transaction.

 

(d)          Minimum
Adjustment. Except as hereinafter provided, no adjustment of the Exercise Price hereunder shall be made if such adjustment
results in a change of the Exercise Price then in effect of less than one dollar ($1.00) per unit. Any adjustment of less than
one dollar ($1.00) per unit of any Exercise Price shall be carried forward and shall be made at the time of and together with any
subsequent adjustment which, together with adjustment or adjustments so carried forward, amounts to one dollar ($1.00) per unit
or more. However, upon exercise of this Warrant, the Company shall make all necessary adjustments (to the nearest cent) not theretofore
made to the Exercise Price up to and including the effective date upon which this Warrant is exercised.

 

(e)          Notice
of Adjustments. Whenever the Exercise Price shall be adjusted pursuant to this Section 3, the Company shall promptly deliver
a certificate signed by the President or a Vice President and by the Chief Financial Officer, Treasurer or an Assistant Treasurer
or the Secretary or an Assistant Secretary of the Company, setting forth, in reasonable detail, the event requiring the adjustment,
the amount of the adjustment, the method by which such adjustment was calculated (including a description of the basis on which
the Board of Directors of the Company made any determination hereunder), by first class mail postage prepaid to each Warrantholder.

 

(f)          Capital
Reorganizations and Other Reclassifications. In case of any capital reorganization of the Company, or of any reclassification
of the Units (other than a reclassification, subdivision or combination of Units referred to in Paragraph 3(a)), this Warrant shall,
after such capital reorganization, reclassification of Units, consolidation, merger, or sale, be immediately exercisable, upon
the terms and conditions specified in this Warrant, for the kind, amount and number of Units or other securities, assets, or cash
to which a holder of the number of Units purchasable (at the time of such capital reorganization, reclassification of Units, consolidation,
merger or sale) upon exercise of this Warrant would have been entitled to receive upon such capital reorganization, reclassification
of Units, consolidation, merger, or sale; and in any such case, if necessary, the provisions set forth in this Section 3 with respect
to the rights and interests thereafter of the Warrantholder shall be appropriately adjusted so as to be applicable, as nearly equivalent
as possible, to any Units or other securities, assets, or cash thereafter deliverable on the exercise of this Warrant. The Company
shall not effect any such consolidation, merger, or sale, unless prior to or simultaneously with the consummation thereof the successor
corporation or entity (if other than the Company) resulting from such consolidation or merger or the corporation or entity purchasing
such assets or other appropriate corporation or entity shall assume, by written instrument, the obligation to deliver to the Warrantholder
such Units, securities, assets, or cash as, in accordance with the foregoing provisions, such holders may be entitled to purchase
and the other obligations hereunder. The subdivision or combination of Units at any time outstanding into a greater or lesser number
of Units shall not be deemed to be a reclassification of the Units for purposes of this Paragraph 3(f).

 

    	 	5	 

     

    

 

(g)          Adjustments
to Other Securities. In the event that at any time, as a result of an adjustment made pursuant to this Section 3, the Warrantholder
shall become entitled to purchase any Units or securities of the Company other than the Units, thereafter the number of such other
Units or securities so purchasable upon exercise of each Warrant and the exercise price for such Units or securities shall be subject
to adjustment from time to time in a manner and on terms as nearly equivalent as possible to the provisions with respect to the
Units contained in Paragraphs 3(a) through (d), inclusive.

 

(h)          Deferral
of Issuance of Additional Units in Certain Circumstances. In any case in which this Section 3 shall require that an adjustment
in the Exercise Price be made effective as of a record date for a specified event, the Company may elect to defer until the occurrence
of such event issuing to the Warrantholder exercised after such record date the Units, if any, issuable upon such exercise over
and above the Units, if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such adjustment;
provided, however, that the Company shall deliver as soon as practicable to such holder a due bill or other appropriate
instrument provided by the Company evidencing such holder’s right to receive such additional Units upon the occurrence of
the event requiring such adjustment.

 

(i)          Initial
Investment. Notwithstanding the foregoing, the number of Units for which this Warrant shall be exercisable and the Exercise
Price shall not adjusted in connection with the initial investment of up to $500,000 by or on behalf of the member of the Company.

 

4.          Replacement
of Securities. If this Warrant shall be lost, stolen, mutilated or destroyed, the Company shall, on such terms as to indemnity
or otherwise as the Company may in its discretion reasonably impose, issue a new warrant of like tenor or date representing in
the aggregate the right to subscribe for and purchase the number of Units which may be subscribed for and purchased hereunder.
Any such new warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen,
mutilated or destroyed warrant shall be at any time enforceable by anyone.

5.          Registration. This
Warrant shall be numbered and shall be registered in a register (the “Warrant Register”) maintained at the Company
Offices as they are issued. The Warrant Register shall list the name, address and Social Security or other Federal Identification
Number, if any, of all warrantholders. The Company shall be entitled to treat the Warrantholder as set forth in the Warrant Register
as the owner in fact of this Warrant as set forth therein for all purposes and shall not be bound to recognize any equitable or
other claim to or interest in this Warrant on the part of any other person, and shall not be liable for any registration or transfer
of this Warrant that is registered or to be registered in the name of a fiduciary or the nominee of a fiduciary unless made with
the actual knowledge that a fiduciary or nominee is committing a breach of trust in requesting such registration of transfer, or
with such knowledge of such facts that its participation therein amounts to bad faith.

 

6.         Transfer.
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED. THIS WARRANT HAS BEEN ACQUIRED, AND ANY UNITS OR ANY OTHER SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT
ARE REQUIRED TO BE ACQUIRED, FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE SOLD, ASSIGNED,
PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR THIS WARRANT AND/OR SUCH UNITS OR
OTHER SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY
TO THE ISSUER OF THIS WARRANT AND SUCH UNITS OR OTHER SECURITIES TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT
AND SUCH STATE SECURITIES LAWS.

 

    	 	6	 

     

    

 

7.         Exchange
of Warrant. This Warrant may be exchanged for another warrant entitling the Warrantholder thereof to purchase a like aggregate
number of Units as this Warrant entitles such Warrantholder to purchase. A Warrantholder desiring to so exchange this Warrant shall
make such request in writing delivered to the Company, and shall surrender this Warrant therewith. Thereupon, the Company shall
execute and deliver to the person entitled thereto a new warrant or warrants, as the case may be, as so requested.

 

8.         Notices.
All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified
mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed:

 

If to the Company:

 

TO PHARMACEUTICALS LLC

One Old Country Road

Carle Place, New York 11514

Fax: (646) 786–4005

Email: barryfarkas1@gmail.com

Attention: Barry Farkas

 

With a copy to:

 

Abrams, Fensterman, Fensterman,

Eisman, Formato, Ferrara & Wolf, LLP

1111 Marcus Avenue, Suite 107

Lake Success, New York 11042

Telephone: (516) 328-2300

Facsimile: (516) 328-6638

Attention: Neil M. Kaufman

Email: nkaufman@abramslaw.com

 

If to the Warrantholder:

 

Sidney Taubenfeld

247 West 87th Street, Apt. 7G

New York, New York 10024

Email: staub18@yahoo.com

 

With a copy to:

 

Michael Schneider, Esq.

11 East 44th Street – 19th
Fl.

New York, New York 10017

Telephone: (212) 888-2100

Facsimile: (646) 461-1781

Email: michael@mslaw-us.com

 

Each such notice or other communication
shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger
or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying
next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of
its receipt or five (5) days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United
States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer, if
sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s
next business day, or (iv) if sent via electronic mail, upon its delivery, if sent during normal business hours of the recipient,
or if not sent during normal business hours of the recipient, then on the recipient’s next business day.

 

    	 	7	 

     

    

 

9.         Miscellaneous.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination is sought. This Warrant is deemed to have been
delivered in the State of New York and shall be construed and enforced in accordance with and governed by the laws of such State,
without regard to its conflicts of laws principles. The headings in this Warrant are for purposes of reference only, and shall
not limit or otherwise affect any of the terms hereof.

 

10.         Expiration.
Unless as hereinafter provided, the right to exercise this Warrant shall expire at the Expiration Date.

 

[Signature Page Follows]

 

    	 	8	 

     

    

 

TO PHARMACEUTICALS LLC

[SIGNATURE PAGE TO WARRANT TO PURCHASE UNITS

 

Dated: March 9, 2015

 

	 	TO PHARMACUETICALS LLC
	 	By: TO HOLDING GROUP LLC, Manager
	 	 	By: TO INVESTOR LLC, Manager
	 	 	 
	 	 	By: 	 /s/ Berel
    Farkas                                                             
	 	 	Name:  	Berel
    Farkas
	 	 	Title:  	Authorize Signatory
	 	 	 
	 	EMPLOYEE:
	 	 	 
	 	 	/s/
    Sidney Taubenfeld
	 	 	Sidney Taubenfeld 

 

    	 	9	 

     

    

 

EXHIBIT
A 

EXERCISE
FORM

 

	 	Dated:____________________, ___

 

TO
PHARMACEUTICALS LLC:

 

The
undersigned hereby irrevocably elects to exercise the within Warrant, to the extent of purchasing __________________ Units, and
hereby makes payment of the Exercise Price in payment of the actual Exercise Price therefor as follows:

 

 ̈$_________________
by certified or official bank check payable to the order of the Company or by wire transfer.

 

 ̈$_________________
by withholding Warrant Units issuable upon exercise of this Warrant;

 

 ̈$_________________
by surrendering to the Company (x) $__________ for Warrant Units previously acquired by the Warrantholder, and/or (y) $_____________
for other securities of the Company.

 

INSTRUCTIONS
FOR REGISTRATION OF STOCK

 

	Name:	 	 
	 	 	(Please type or print in block letters)
	 	 	 
	Taxpayer Identification Number:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Signature:	 	 
	 	 	(Signature must conform in all respects to the name of the Warrantholder as set forth on the face of this Warrant)

 

    	 	10	 

     

    

 

EXHIBIT
B 

JOINDER
TO OPERATING AGREEMENT

OF
TO PHARMACEUTICALS LLC

 

This
JOINDER (the “Joinder”)
to Operating Agreement of TO Pharmaceuticals LLC, a Delaware limited liability company (the “Company”),
dated as of October 21, 2015, as amended or restated from time to time (the “Agreement”),
is made and entered into as of the date below, by and between the Company and the unitholder listed below (“Unitholder”).
Capitalized terms used herein but not otherwise defined shall have the meanings set forth in the Agreement.

 

WHEREAS,
on the date hereof, Unitholder has acquired certain Units, and the Agreement and the Company require Unitholder, as a holder
of such Interest, to become a party to the Agreement, and Unitholder agrees to do so in accordance with the terms hereof.

 

NOW,
THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties to this Joinder hereby agree as follows:

 

A.           Agreement
to be Bound. Unitholder hereby (i) acknowledges that he/she/it has received and reviewed a complete copy of the Agreement
and (ii) agrees that upon execution of this Joinder, he/she/it shall become a party to the Agreement and shall be fully bound by,
and subject to, all of the covenants, terms and conditions of the Agreement as though an original party thereto and shall be deemed,
and is hereby admitted as, a Member for all purposes thereof and entitled to all the rights incidental thereto.

 

B.           Governing
Law. This Agreement
and the rights of the parties hereunder shall be interpreted in accordance with the laws of the State of Delaware, and all rights
and remedies shall be governed by such laws without regard to principles of conflicts of laws.

 

C.           Headings;
Counterparts. The headings of this Joinder are inserted for convenience only and do not constitute a part of this Joinder.
This Joinder may be executed in multiple counterparts (and may be transmitted via facsimile or other electronic submission) each
of which shall be deemed to be an original and all of which taken together shall constitute one and the same agreement

 

IN
WITNESS WHEREOF, the parties hereto have executed this Joinder to the Operating Agreement of TO Pharmaceuticals LLC as of the
date set forth below.

 

	UNITHOLDER:	 	UNITHOLDER:
	If an Entity:	 	If an Individual:
	 	 	 	 	 	 
	By:	 	 	 	 	 
	 	Name:	 	 	Name:	 
	 	Title:	 	 	Date:	 
	 	Date:	 	 	Address:	 
	 	Address:	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

 

	TO PHARMACEUTICALS LLC:	 	FOR COMPANY USE ONLY:
	 	 	 	 
	By:	 	 	 	Number of Units:	 
	 	Name:	             	 	Class of Units:	 
	 	Title:	 	 	Capital Contribution:	 
	 	Date:	 	 	 	 

 

    	 	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]